ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Author :
admin
Date :
2019-08-20 21:08
IR News Letter - Submit Final Abstract to ESMO / Neopharma / Patent. (08/20/2019)
Prev
IR News Letter - Pre-NDA Meeting (08/09/2019)
IR News Letter - Current Status of Clinical Trials and Indications for Rivoceranib (08/29/2019)
Next
List